TFAM and neoplasm: In detail, a patient with metastatic well-differentiated NET, likely originating from the small intestine, bearing an ETS Variant Transcription Factor 6-NTRK3 fusion, was treated with entrectinib in the STARTRK2 trial with a rapid and meaningful tumor response preceded by initial tumor growth and necrosis (60).